Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospects for immunotherapy of malignant disease.
Morris EC, Bendle GM, Stauss HJ. Morris EC, et al. Clin Exp Immunol. 2003 Jan;131(1):1-7. doi: 10.1046/j.1365-2249.2003.02055.x. Clin Exp Immunol. 2003. PMID: 12519379 Free PMC article. Review.
Exploiting T cell receptor genes for cancer immunotherapy.
Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ. Xue S, et al. Clin Exp Immunol. 2005 Feb;139(2):167-72. doi: 10.1111/j.1365-2249.2005.02715.x. Clin Exp Immunol. 2005. PMID: 15654813 Free PMC article. Review.
Engineered T cells Flt around their targets.
Morris EC. Morris EC. Nat Immunol. 2020 Aug;21(8):831-832. doi: 10.1038/s41590-020-0740-3. Nat Immunol. 2020. PMID: 32647320 No abstract available.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Donnadieu E, et al. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. J Immunother Cancer. 2022. PMID: 35577500 Free PMC article. Review.
Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation.
Kennedy A, Waters E, Rowshanravan B, Hinze C, Williams C, Janman D, Fox TA, Booth C, Pesenacker AM, Halliday N, Soskic B, Kaur S, Qureshi OS, Morris EC, Ikemizu S, Paluch C, Huo J, Davis SJ, Boucrot E, Walker LSK, Sansom DM. Kennedy A, et al. Among authors: morris ec. Nat Immunol. 2022 Sep;23(9):1365-1378. doi: 10.1038/s41590-022-01289-w. Epub 2022 Aug 23. Nat Immunol. 2022. PMID: 35999394 Free PMC article.
Exploiting alloreactivity for tumour immunotherapy.
Stauss HJ, Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Morris E. Stauss HJ, et al. Vox Sang. 2004 Jul;87 Suppl 2:227-9. doi: 10.1111/j.1741-6892.2004.00493.x. Vox Sang. 2004. PMID: 15209922 Review. No abstract available.
137 results